Clinical Trials Office

罗林斯癌症中心（HCC）临床试验办公室（CTO）为在南卡罗来纳州医科大学（MUSC）开展癌症临床试验提供了一个集中办公室。HCC CTO的目的是提供有效和高效的临床研究基础设施，以支持研究者和临床医生开发和实施临床研究。首席技术干事的主要职能是： 协助HCC主要研究者启动和管理研究，包括科学、伦理、财务和操作审查所需的准备和沟通，以及对年度监管审查的持续支持 协助临床医生筛选和招募患者进行临床研究 协调并确保完成患者特定的研究要求 为临床研究提供数据管理支持为内部和外部质量和合规性稽查准备医疗和研究记录为临床和CTO工作人员以及新研究者提供与开展临床研究的最佳实践相关的培训和教育向HCC医生、转诊医生和公众传达临床研究的可用性管理HCC临床试验网络，在过去的十年中，CTO扩大了其容量，服务和能力，并被认为是 MUSC最有效和最高效的临床研究单位。目前，HCC CTO为21个MUSC部门/部门提供服务，临床试验组合包括来自所有主要NCI合作组试验的研究（例如，SWOG、RTOG、GOG、COG、ACRIN、ACoSOG、NSABP）、行业申办的研究和越来越多的制药商发起的研究。在过去的五年中，治疗性临床试验的累积增加了四倍，现在占新发HCC癌症病例总数的11%。

The Rollings Cancer Center (HCC) Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina (MUSC). The purpose of the HCC CTO is to provide an effective and efficient clinical research infrastructure to support investigators and clinicians in developing and implementing clinical research studies. The major functions of the CTO are to: Assist HCC Principal Investigators in the activation and administration of studies, including the preparations and communications required for scientific, ethical, financial and operational reviews as well as ongoing support for annual regulatory reviews Assist clinicians in screening and enrolling patients for clinical research studies Coordinate and ensure the completion of patient-specific study requirements Provide data management support for clinical research studies Prepare medical and research records for internal and external quality and compliance audits Provide training and education pertaining to the best practices in conducting clinical studies to clinical and CTO staff as well as new investigators Communicate the availability of clinical studies to HCC physicians, referring physicians and the public Administer the HCC Clinical Trials Network, which promotes statewide clinical trial access Over the past decade the CTO has expanded its capacity, services and capabilities and is considered one of MUSC's most effective and efficient clinical research units. Currently, the HCC CTO provides services to twenty-one MUSC departments/divisions and the clinical trials portfolio includes studies from all of the major NCI Cooperative Group trials (e.g., SWOG, RTOG, GOG, COG, ACRIN, ACoSOG, NSABP), industry sponsored studies and a growing number of investigator-initiated studies. Accrual to therapeutic clinical trials has quadrupled during the past five years and now represents 11% of total new HCC cancer cases.